Semaglutide vs GHK-Cu
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SemaglutideSkin & CosmeticRecovery & RepairAnti-Aging & Longevity
GHK-Cu- Summary
- Semaglutide is an FDA-approved GLP-1 receptor agonist originally developed for type 2 diabetes that has proven remarkably effective for weight loss. Clinical trials show average 15–20% body weight reduction. It is marketed as Ozempic (diabetes) and Wegovy (weight management).
- GHK-Cu is a naturally occurring copper complex that declines with age. It is one of the most studied anti-aging peptides, known for powerful skin rejuvenation, wound healing, and tissue remodeling effects.
- Half-Life
- ~7 days
- 2–4 hours
- Admin Route
- SubQ, Oral
- SubQ, Topical
- Research
- —
- —
- Typical Dose
- 0.25 mg → 0.5 mg → 1 mg → 1.7 mg → 2.4 mg
- 1–3 mg
- Frequency
- Once weekly, subcutaneous
- 3–5 times per week
- Key Benefits
- Average 15–20% body weight reduction in clinical trials (STEP trials)
- Significant reduction in appetite and food cravings
- Improvement in blood sugar control and insulin sensitivity
- Reduces cardiovascular risk (SELECT trial: 20% reduction in MACE)
- May reduce risk of kidney disease
- Improves metabolic markers (cholesterol, blood pressure)
- FDA-approved — extensively studied with robust safety data
- Weekly dosing convenience
- Reduces wrinkles and fine lines
- Improves skin firmness and elasticity
- Accelerates wound healing
- Reduces inflammation and oxidative damage
- Promotes hair growth and thickness
- Supports collagen and elastin production
- May improve overall skin health and appearance
- Resets aged fibroblast behavior
- Anti-fibrotic — reduces scar tissue formation
- Side Effects
- Nausea (most common, especially during titration)
- Vomiting
- Diarrhea or constipation
- Abdominal discomfort
- +4 more
- Temporary blue-green discoloration at injection site (from copper — harmless)
- Post-injection sting (brief)
- Skin irritation with topical use (rare)
- Stacks With
- —
- —